BioNTech posts results for mpox vaccine BNT166a Phase I/II trial NCT05988203
Results were first posted for BioNTech's dose-escalation study of investigational RNA-based mpox vaccine BNT166a, run across three substudies in vaccinia-naive and vaccinia-experienced adults.
BioNTech had one notable registry update this week, with results posted for its mpox vaccine trial.
- **BNT166a mpox vaccine, Phase I/II (NCT05988203):** Results were first posted on 2026-09-15 for this trial, which the sponsor describes as a dose-escalation, Phase I/II study evaluating the safety, tolerability, reactogenicity and immunogenicity of the investigational RNA-based multivalent vaccine candidate BNT166a for active immunization against monkeypox (mpox)1. The study enrolled 96 participants across three conducted substudies, after the sponsor decided not to conduct SSC, thus three substudies (SSA, SSB, and SSD) were conducted1, and also decided to not activate the groups with BNT166c1, a second candidate originally planned for testing. The trial reached primary completion on 2025-08-25 and study completion on 2026-03-04.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.